What is he best known for?
The fields of study he is best known for:
- Organic chemistry
- Enzyme
- Catalysis
His main research concerns Stereochemistry, Acetylcholinesterase, Organic chemistry, Pharmacology and Tacrine.
His Stereochemistry research is multidisciplinary, relying on both Nucleophile and Cholinesterase.
José Marco-Contelles has researched Acetylcholinesterase in several fields, including Structure–activity relationship, Disease and Neuroprotection.
In his research on the topic of Organic chemistry, Chemical reaction and Dissociation is strongly related with Medicinal chemistry.
His Pharmacology study integrates concerns from other disciplines, such as Acetylcholinesterase inhibitor, Galantamine, Donepezil, Alzheimer's disease and Monoamine oxidase A.
His Tacrine study combines topics in areas such as Neurotoxicity and Trolox.
His most cited work include:
- Recent advances in the multitarget‐directed ligands approach for the treatment of Alzheimer's disease (311 citations)
- Recent developments in the metal-catalyzed reactions of metallocarbenoids from propargylic esters. (207 citations)
- Synthesis and Pharmacology of Galantamine (168 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Stereochemistry, Organic chemistry, Pharmacology, Neuroprotection and Acetylcholinesterase.
The Stereochemistry study combines topics in areas such as Chemical synthesis and Enzyme.
His Pharmacology course of study focuses on Antioxidant and Melatonin.
José Marco-Contelles interconnects Stroke, Oxidative stress and Ischemia in the investigation of issues within Neuroprotection.
His Acetylcholinesterase study is concerned with the larger field of Biochemistry.
His Tacrine research includes elements of Alzheimer's disease and Disease.
He most often published in these fields:
- Stereochemistry (28.35%)
- Organic chemistry (27.32%)
- Pharmacology (21.13%)
What were the highlights of his more recent work (between 2017-2021)?
- Pharmacology (21.13%)
- Neuroprotection (16.75%)
- Antioxidant (9.79%)
In recent papers he was focusing on the following fields of study:
Pharmacology, Neuroprotection, Antioxidant, Tacrine and Acetylcholinesterase are his primary areas of study.
José Marco-Contelles studies Cholinesterase which is a part of Pharmacology.
His Neuroprotection research is multidisciplinary, incorporating perspectives in Nitrone, Superoxide and Ischemia.
His study in Tacrine is interdisciplinary in nature, drawing from both Alzheimer's disease, Disease, Cholinergic and Drug.
His research on Acetylcholinesterase focuses in particular on Butyrylcholinesterase.
The study of IC50 is intertwined with the study of Stereochemistry in a number of ways.
Between 2017 and 2021, his most popular works were:
- Alzheimer's Disease, the "One-Molecule, One-Target" Paradigm, and the Multitarget Directed Ligand Approach. (48 citations)
- Contilisant, a Tetratarget Small Molecule for Alzheimer's Disease Therapy Combining Cholinesterase, Monoamine Oxidase Inhibition, and H3R Antagonism with S1R Agonism Profile. (17 citations)
- Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease. (17 citations)
In his most recent research, the most cited papers focused on:
- Organic chemistry
- Enzyme
- Catalysis
José Marco-Contelles mostly deals with Pharmacology, Tacrine, Neuroprotection, Cholinesterase and Receptor.
His Pharmacology research is multidisciplinary, incorporating elements of IC50, Donepezil and Antioxidant.
Acetylcholinesterase covers José Marco-Contelles research in Tacrine.
José Marco-Contelles has included themes like Lead compound and Drug in his Neuroprotection study.
His research in Receptor antagonist tackles topics such as Senile plaques which are related to areas like Stereochemistry.
His Stereochemistry study frequently draws connections to adjacent fields such as Monoamine oxidase.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
